A detailed history of Great Lakes Advisors, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Great Lakes Advisors, LLC holds 199,253 shares of RARE stock, worth $8.72 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
199,253
Previous 32,521 512.69%
Holding current value
$8.72 Million
Previous $1.34 Million 728.44%
% of portfolio
0.1%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$40.21 - $59.36 $6.7 Million - $9.9 Million
166,732 Added 512.69%
199,253 $11.1 Million
Q2 2024

Aug 05, 2024

BUY
$37.42 - $51.61 $235,596 - $324,936
6,296 Added 24.01%
32,521 $1.34 Million
Q1 2024

May 08, 2024

SELL
$43.02 - $53.69 $66,594 - $83,112
-1,548 Reduced 5.57%
26,225 $1.22 Million
Q4 2023

Feb 08, 2024

SELL
$31.73 - $49.19 $878,096 - $1.36 Million
-27,674 Reduced 49.91%
27,773 $1.33 Million
Q3 2023

Nov 07, 2023

SELL
$34.92 - $46.66 $496,422 - $663,318
-14,216 Reduced 20.41%
55,447 $1.98 Million
Q2 2023

Aug 10, 2023

SELL
$37.35 - $52.15 $1.85 Million - $2.58 Million
-49,555 Reduced 41.57%
69,663 $3.21 Million
Q1 2023

May 10, 2023

BUY
$36.99 - $48.71 $4.41 Million - $5.81 Million
119,218 New
119,218 $4.78 Million
Q2 2021

Aug 11, 2021

SELL
$92.19 - $115.71 $13.7 Million - $17.2 Million
-149,020 Closed
0 $0
Q1 2021

May 03, 2021

BUY
$106.9 - $167.73 $933,664 - $1.46 Million
8,734 Added 6.23%
149,020 $17 Million
Q4 2020

Feb 09, 2021

BUY
$84.4 - $177.39 $11.8 Million - $24.9 Million
140,286 New
140,286 $19.4 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.06B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Great Lakes Advisors, LLC Portfolio

Follow Great Lakes Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Lakes Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Lakes Advisors, LLC with notifications on news.